Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. (Record no. 7478)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02229 am a2200193 4500 |
| 001 - CONTROL NUMBER | |
| control field | 2286 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Terms of availability | 0.00 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | Annals of Oncology, Volume 20, Issue 5, Pages 862 - 7, 2009. |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | PUBLICATIONS ARCHIVE CROW |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Crown, John |
| 9 (RLIN) | 34721 |
| 245 ## - TITLE STATEMENT | |
| Title | Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2009. |
| 490 ## - SERIES STATEMENT | |
| Series statement | Staff Publications |
| Volume/sequential designation | Staff Publications- Crown, John |
| 500 ## - GENERAL NOTE | |
| General note | The print version of this article is held in the Oncology Resource Centre (Box 1). |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | BACKGROUND: No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC). Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC. We studied the activity of EGFR antagonists alone, and in combination with chemotherapy, in TNBC cell lines. MATERIALS AND METHODS: EGFR and phosphorylated EGFR were measured by enzyme-linked immunosorbent assay. Sensitivity to EGFR inhibitors alone and in combination with chemotherapy was assessed. Effects of gefitinib on EGFR signalling and cell cycle were also examined. RESULTS: EGFR was overexpressed in the TNBC compared with the human epidermal growth factor receptor 2 (HER-2)-positive cell lines. Phosphorylation of EGFR was detected in the TNBC cells in response to epidermal growth factor stimulation and was blocked by gefitinib treatment. However, the TNBC cell lines were less sensitive to EGFR inhibition than the HER-2-positive cell lines. Response to gefitinib was associated with reduced phosphorylation of both mitogen activated protein kinase (MAPK) and Akt and induction of G(1) arrest. Gefitinib enhanced response to both carboplatin and docetaxel in the TNBC cells, and the triple combination of gefitinib, carboplatin and docetaxel was synergistic. CONCLUSIONS: Although the TNBC cells are less sensitive to EGFR inhibition than the HER-2-positive cell lines, gefitinib enhanced response to chemotherapy. Gefitinib combined with carboplatin and docetaxel warrants further investigation in TNBC. |
| 9 (RLIN) | 35119 |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Corkery, Bill |
| 9 (RLIN) | 35120 |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Clynes, M. |
| 9 (RLIN) | 35121 |
| 710 ## - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | ST. LUKE'S PUBLICATION ARCHIVE |
| 9 (RLIN) | 32511 |
| Withdrawn status | Lost status | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Cost, normal purchase price | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Withdrawn | Not Lost | Not Damaged | Available for Loan | St. Luke’s Radiation Oncology Network Dublin | St. Luke’s Radiation Oncology Network Dublin | AR | 14/05/2018 | 0.00 | PUBLICATIONS ARCHIVE CROW | 39015000019805 | 14/05/2018 | 14/05/2018 | 2 Week Loan |